Biotech company aTyr Pharma announced that its lead candidate efzofitimod did not meet the primary endpoint in a Phase 3 study evaluating steroid tapering efficacy in patients with pulmonary sarcoidosis. Despite showing some reduction in corticosteroid use, the differences compared to placebo were not statistically significant, leading to an approximate 80% plunge in the company’s stock price. Plans for regulatory discussions continue amid the setback. Efzofitimod’s failure highlights the challenges in treating inflammatory lung diseases and raises questions on the drug’s commercial viability.